(SY1) Symrise - Overview
Stock: Fragrances, Flavorings, Cosmetics, Nutraceuticals, Probiotics
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.15% |
| Yield on Cost 5y | 1.24% |
| Yield CAGR 5y | 5.46% |
| Payout Consistency | 96.9% |
| Payout Ratio | 62.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 21.9% |
| Relative Tail Risk | -5.07% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.12 |
| Alpha | -27.73 |
| Character TTM | |
|---|---|
| Beta | -0.003 |
| Beta Downside | -0.074 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.53% |
| CAGR/Max DD | -0.18 |
Description: SY1 Symrise January 03, 2026
Symrise AG (XETRA:SY1) is a global supplier of fragrances, flavorings, cosmetic base materials, active ingredients, and functional solutions. It serves customers across Europe, Africa, the Middle East, North America, the Asia-Pacific, and Latin America through two main divisions: Taste, Nutrition & Health, which delivers functional and natural ingredients for food, beverages, pet food, fish feed, and probiotics; and Scent & Care, which produces fragrance compounds, aroma molecules, cosmetic actives, and mint flavors for perfumes, personal-care, cleaning, and oral-care products.
Key recent metrics (FY 2023) show revenue of roughly €5.2 billion, an operating margin of 10.5 % and R&D investment of about 6 % of sales-reflecting the company’s focus on innovation. The natural-ingredients franchise grew ~12 % YoY, driven by consumer demand for clean-label, plant-based, and sustainably sourced products, while the fragrance business benefited from a rebound in premium personal-care spending post-pandemic. Core sector drivers include tightening food-safety regulations, rising demand for “green” and allergen-free formulations, and macro-level growth in emerging-market consumer goods consumption.
For a deeper quantitative assessment of Symrise’s valuation and risk profile, the ValueRay platform offers a concise, data-rich overview you may find useful.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 506.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.65 > 1.0 |
| NWC/Revenue: 18.53% < 20% (prev 37.33%; Δ -18.80% < -1%) |
| CFO/TA 0.11 > 3% & CFO 813.5m > Net Income 506.9m |
| Net Debt (2.05b) to EBITDA (1.04b): 1.97 < 3 |
| Current Ratio: 1.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (139.7m) vs 12m ago -0.26% < -2% |
| Gross Margin: 40.25% > 18% (prev 0.37%; Δ 3988 % > 0.5%) |
| Asset Turnover: 63.77% > 50% (prev 61.71%; Δ 2.06% > 0%) |
| Interest Coverage Ratio: 6.38 > 6 (EBITDA TTM 1.04b / Interest Expense TTM 115.9m) |
Altman Z'' 3.22
| A: 0.12 (Total Current Assets 2.80b - Total Current Liabilities 1.88b) / Total Assets 7.73b |
| B: 0.25 (Retained Earnings 1.94b / Total Assets 7.73b) |
| C: 0.09 (EBIT TTM 739.5m / Avg Total Assets 7.82b) |
| D: 0.93 (Book Value of Equity 3.71b / Total Liabilities 3.99b) |
| Altman-Z'' Score: 3.22 = A |
Beneish M -3.16
| DSRI: 0.98 (Receivables 1.02b/1.02b, Revenue 4.99b/4.88b) |
| GMI: 0.93 (GM 40.25% / 37.47%) |
| AQI: 0.96 (AQ_t 0.43 / AQ_t-1 0.44) |
| SGI: 1.02 (Revenue 4.99b / 4.88b) |
| TATA: -0.04 (NI 506.9m - CFO 813.5m) / TA 7.73b) |
| Beneish M-Score: -3.16 (Cap -4..+1) = AA |
What is the price of SY1 shares?
Over the past week, the price has changed by +2.11%, over one month by +5.01%, over three months by +1.31% and over the past year by -24.78%.
Is SY1 a buy, sell or hold?
What are the forecasts/targets for the SY1 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 95.8 | 32% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 68.4 | -5.8% |
SY1 Fundamental Data Overview February 03, 2026
P/E Trailing = 19.5758
P/E Forward = 17.0648
P/S = 1.9916
P/B = 2.6673
P/EG = 2.3265
Revenue TTM = 4.99b EUR
EBIT TTM = 739.5m EUR
EBITDA TTM = 1.04b EUR
Long Term Debt = 1.27b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.01b EUR (from shortTermDebt, last quarter)
Debt = 2.42b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.05b EUR (from netDebt column, last quarter)
Enterprise Value = 11.98b EUR (9.93b + Debt 2.42b - CCE 369.7m)
Interest Coverage Ratio = 6.38 (Ebit TTM 739.5m / Interest Expense TTM 115.9m)
EV/FCF = 22.65x (Enterprise Value 11.98b / FCF TTM 529.0m)
FCF Yield = 4.42% (FCF TTM 529.0m / Enterprise Value 11.98b)
FCF Margin = 10.61% (FCF TTM 529.0m / Revenue TTM 4.99b)
Net Margin = 10.16% (Net Income TTM 506.9m / Revenue TTM 4.99b)
Gross Margin = 40.25% ((Revenue TTM 4.99b - Cost of Revenue TTM 2.98b) / Revenue TTM)
Gross Margin QoQ = 41.49% (prev 41.49%)
Tobins Q-Ratio = 1.55 (Enterprise Value 11.98b / Total Assets 7.73b)
Interest Expense / Debt = 1.88% (Interest Expense 45.3m / Debt 2.42b)
Taxrate = 26.71% (49.2m / 184.4m)
NOPAT = 541.9m (EBIT 739.5m * (1 - 26.71%))
Current Ratio = 1.49 (Total Current Assets 2.80b / Total Current Liabilities 1.88b)
Debt / Equity = 0.65 (Debt 2.42b / totalStockholderEquity, last quarter 3.71b)
Debt / EBITDA = 1.97 (Net Debt 2.05b / EBITDA 1.04b)
Debt / FCF = 3.87 (Net Debt 2.05b / FCF TTM 529.0m)
Total Stockholder Equity = 3.85b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.48% (Net Income 506.9m / Total Assets 7.73b)
RoE = 13.18% (Net Income TTM 506.9m / Total Stockholder Equity 3.85b)
RoCE = 14.46% (EBIT 739.5m / Capital Employed (Equity 3.85b + L.T.Debt 1.27b))
RoIC = 8.82% (NOPAT 541.9m / Invested Capital 6.14b)
WACC = 5.01% (E(9.93b)/V(12.35b) * Re(5.90%) + D(2.42b)/V(12.35b) * Rd(1.88%) * (1-Tc(0.27)))
Discount Rate = 5.90% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.03%
[DCF Debug] Terminal Value 83.03% ; FCFF base≈586.1m ; Y1≈443.9m ; Y5≈269.7m
Fair Price DCF = 45.21 (EV 8.37b - Net Debt 2.05b = Equity 6.32b / Shares 139.8m; r=5.90% [WACC]; 5y FCF grow -28.75% → 2.90% )
EPS Correlation: -11.37 | EPS CAGR: -47.44% | SUE: 0.0 | # QB: 0
Revenue Correlation: -15.62 | Revenue CAGR: 7.94% | SUE: -0.01 | # QB: 0
EPS next Year (2026-12-31): EPS=4.00 | Chg30d=-0.027 | Revisions Net=+0 | Growth EPS=+9.5% | Growth Revenue=+2.4%